Fig. 3
From: The landscape overview of CD47-based immunotherapy for hematological malignancies
Inhibiting CD47/SIRPα axis regulates the fate of cancer cells. Inhibiting the CD47/SIRPα axis can (A) directly enhance phagocytosis of macrophages to tumor cells; B transform tumor-associated macrophages into an antitumor state and increase the recruitment of macrophages in tumors; C promote phagocytosis by dendritic cells and antigen presentation to CD8 + T-cells; (D) destroy tumor cells by natural killer cell-mediated ADCC and CDC; E increase tumor cell death, inhibit tumor cell proliferation, and prevent tumor cell migration. Abbreviation: CD47, cluster of differentiation 47; SIRPα, signal-regulatory protein α; ACDD: antibody-dependent cellular cytotoxicity; CDC: complement-dependent cytotoxicity